pharmaphorum

Could a Novo error set up early GLP-1 generics in Canada?

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...
pharmaphorum

FDA pilots fast-track scheme for US-made generics

In another move designed to reduce the US' reliance on imported medicines, the FDA has launched a pilot of fast-track reviews for generics tested and made in domestic facilities. According to the ...
FiercePharma

Lowering FDA fees would spur generics manufacturing in US, Mark Cuban says

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...
STAT

Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
C&EN

Looming GLP-1 drug patent expirations draw generics firms

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
Investopedia

Generic Brands Explained: Definition, Types, and Comparison to Store Brands

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...